Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ICCC

ICCC - ImmuCell Corp Stock Price, Fair Value and News

$6.270.00 (0.00%)
Market Closed

42/100

ICCC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

42/100

ICCC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$5.33

Target 3M

$6.02

Target 6M

$5.78

ICCC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ICCC Price Action

Last 7 days

-7.8%

Last 30 days

2.0%

Last 90 days

3.0%

Trailing 12 Months

16.8%

ICCC RSI Chart

ICCC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ICCC Valuation

Market Cap

56.7M

Price/Earnings (Trailing)

24.41

Price/Sales (Trailing)

2.04

EV/EBITDA

11.37

Price/Free Cashflow

79.29

ICCC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$5.33

Target 3M

$6.02

Target 6M

$5.78

ICCC Fundamentals

ICCC Revenue

Revenue (TTM)

27.8M

Rev. Growth (Yr)

-8.41%

Rev. Growth (Qtr)

-14.57%

ICCC Earnings

Earnings (TTM)

2.3M

Earnings Growth (Yr)

80.08%

Earnings Growth (Qtr)

-127.84%

ICCC Profitability

EBT Margin

8.42%

Return on Equity

7.8%

Return on Assets

5.08%

Free Cashflow Yield

1.26%

ICCC Investor Care

Shares Dilution (1Y)

1.51%

Diluted EPS (TTM)

0.28

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202527.3M28.3M27.8M0
202418.7M20.7M21.3M26.5M
202316.0M15.7M16.3M14.9M
202221.1M20.5M20.1M18.6M
202114.5M16.1M17.5M19.2M
202014.2M14.5M15.2M15.3M
201912.5M12.2M13.0M13.7M
20189.8M11.0M11.2M11.0M
201710.1M9.5M9.5M10.4M
201610.1M10.5M10.0M9.5M
20158.6M9.0M9.7M10.2M
20146.2M6.4M7.0M7.6M
20135.5M5.7M5.9M6.0M
20125.3M5.2M5.3M5.4M
20114.6M4.8M4.9M5.1M
20100004.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About ImmuCell Corp

ICCC
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
 CEO
 WEBSITEhttps://immucell.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES66

ImmuCell Corp Frequently Asked Questions

ICCC is the stock ticker symbol of ImmuCell Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of ImmuCell Corp is 56.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ICCC's fair value in chart for subscribers.

The fair value guage provides a quick view whether ICCC is over valued or under valued. Whether ImmuCell Corp is cheap or expensive depends on the assumptions which impact ImmuCell Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ICCC.

As of Wed Jan 28 2026, ICCC's PE ratio (Price to Earnings) is 24.41 and Price to Sales (PS) ratio is 2.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ICCC PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, ImmuCell Corp has provided 0.007 (multiply by 100 for percentage) rate of return.